Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats

Life Sci. 2022 Nov 1:308:120966. doi: 10.1016/j.lfs.2022.120966. Epub 2022 Sep 21.

Abstract

Aims: Liver cirrhosis defines by regenerative nodules and fibrotic septa, causing a complication called cirrhotic cardiomyopathy (CCM) with chronotropic hypo-responsiveness. In addition to lowering cholesterol levels, statins yield antioxidant and anti-inflammatory effects. In liver diseases animal models, statins have been shown to decrease hepatic inflammation, fibrogenesis, and portal pressure (PP). Therefore, we evaluated the atorvastatin effect on the heart in cirrhotic rats.

Materials and methods: Bile duct ligation (BDL) or sham operation performed on male Wistar rats and grouped as cirrhotic; BDL/Saline, BDL/Ator-7d(days) (Atorvastatin 15 mg/kg/day), and BDL/Ator-14d groups, or control; Sham/Saline, Sham/Ator-7d, and Sham/Ator-14d groups. Corrected QT interval (QTc interval), chronotropic responses, serum brain natriuretic peptides (BNP), heart tumor necrosis factor-α (TNF-α), nuclear factor erythroid 2-related factor 2 (Nrf2), and malondialdehyde (MDA) levels were studied along with atrial Ras homolog family member A (RhoA) and endothelial nitric oxide synthase (eNOS) gene expression.

Key findings: The chronotropic responses decreased in BDL/Saline and increased in BDL/Ator-7d group. The QTc interval, BNP, TNF-α, and MDA levels increased in BDL/Saline and decreased in BDL/Ator-14d group. The Nrf2 level did not change in BDL/Saline and increased in BDL/Ator-14d group. The liver inflammation and fibrosis increased in BDL/Saline and did not affect BDL/Ator-7d and BDL/Ator-14d groups. The RhoA expression was down-regulated in BDL/Saline, BDL/Ator-7d, and BDL/Ator-14d groups. The eNOS expression did not change in BDL/Saline and down-regulated in BDL/Ator-14d group.

Significance: Atorvastatin alleviates the chronotropic hypo-responsiveness and down-regulates the atrial RhoA and eNOS gene expression along with anti-inflammatory, antioxidant, and anti-stress effects in CCM.

Keywords: Atorvastatin; Bile duct ligation (BDL); Chronotropic responses; Cirrhotic cardiomyopathy (CCM); Endothelial nitric oxide synthase (eNOS); Ras homolog family member A (RhoA).

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / metabolism
  • Atorvastatin / metabolism
  • Cholesterol / metabolism
  • Fibrosis
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Ligation
  • Liver / metabolism
  • Liver Cirrhosis / pathology
  • Male
  • Malondialdehyde / metabolism
  • NF-E2-Related Factor 2 / metabolism
  • Natriuretic Peptides / metabolism
  • Nitric Oxide Synthase Type III* / metabolism
  • Rats
  • Rats, Wistar
  • Tumor Necrosis Factor-alpha / metabolism
  • rhoA GTP-Binding Protein / metabolism

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Atorvastatin
  • Cholesterol
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Malondialdehyde
  • Natriuretic Peptides
  • NF-E2-Related Factor 2
  • Nitric Oxide Synthase Type III
  • rhoA GTP-Binding Protein
  • Tumor Necrosis Factor-alpha